We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 32

Will Physician Payment Sunshine Act data usher in a new era of False Claims Act litigation?

  • Reed Smith LLP
  • -
  • USA
  • -
  • April 10 2014

While attention has been focused on Medicare physician payment data released by CMS yesterday, upcoming Sunshine Act data will shine a new spotlight

State prosecutors file consumer protection lawsuit against Toyota

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 18 2010

California state prosecutors have reportedly sued Toyota Motor Corp., alleging it engaged in fraud by concealing evidence of dangerous motor vehicle defects

The enforcement heat increases and Stryker is just the latest

  • Faegre Baker Daniels
  • -
  • USA
  • -
  • October 30 2009

Recent statements by FDA and DOJ officials, including FDA Commissioner Hamburg, promised an increase in enforcement

FDA to increase enforcement actions against corporate officials

  • Faegre Baker Daniels
  • -
  • USA
  • -
  • March 5 2010

Corporate executives have rarely been personal targets of FDA enforcement actions

GAO report calls for increase in FDA criminal prosecutions of company executives

  • Reed Smith LLP
  • -
  • USA
  • -
  • March 15 2010

The GAO recently issued a report entitled "Food and Drug Administration: Improved Monitoring and Development of Performance Measures Needed to Strengthen Oversight of Criminal and Misconduct Investigations," at the request of Senate Finance Committee Ranking Republican Charles Grassley

FDA looks to boost criminal prosecutions

  • Sheppard Mullin Richter & Hampton LLP
  • -
  • USA
  • -
  • March 11 2010

In the wake of a scathing March 4th GAO Report, FDA has informed Congress that it will boost criminal prosecutions of pharmaceutical and food industry executives

Indictment of former GlaxoSmithKline in-house attorney highlights risks and provides lessons for handling document requests in government investigations

  • Jenner & Block
  • -
  • USA
  • -
  • November 23 2010

A former in-house counsel at pharmaceutical company GlaxoSmithKline ("GSK"), Lauren Stevens, was indicted earlier this month for obstruction of a proceeding, false statements, and falsifying or concealing documents for her role in responding to a document request from the Food and Drug Administration ("FDA"

Matrixx Securities fraud case could affect product liability law

  • Squire Patton Boggs
  • -
  • USA
  • -
  • December 10 2010

Sometimes the most significant changes in the law come from unexpected places

New indictment of in-house counsel indicates enhanced efforts to hold corporate executives accountable for food and drug law violations

  • Fish & Richardson PC
  • -
  • USA
  • -
  • November 15 2010

This year, both the Food and Drug Administration (FDA) and Department of Justice have repeatedly signaled to the pharmaceutical and medical device industries that they should expect an increase in the criminal prosecution of individuals for alleged violations of the food and drug laws, with the stated goals of increasing deterrence and greater compliance

Matrixx Initiatives, Inc. v. Siracusano

  • Dorsey & Whitney LLP
  • -
  • USA
  • -
  • March 25 2011

Failure to disclose a statistically insignificant incidence of adverse side effects could lead to significant securities-fraud liability for publicly traded drugmakers, device manufacturers, and others under a recent Supreme Court decision